Author:
De Martin Eleonora,Michot Jean-Marie,Papouin Barbara,Champiat Stéphane,Mateus Christine,Lambotte Olivier,Roche Bruno,Antonini Teresa Maria,Coilly Audrey,Laghouati Salim,Robert Caroline,Marabelle Aurélien,Guettier Catherine,Samuel Didier
Reference37 articles.
1. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial;Hodi;Lancet Oncol,2016
2. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015
3. Cancer and the immune system: basic concepts and targets for intervention;Pardoll;Semin Oncol,2015
4. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012
5. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy;Topalian;Nat Rev Cancer,2016
Cited by
407 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献